```html

Zollinger‑Ellison Syndrome (Primary Hypergastrinemia)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcer disease, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but most commonly presents in middle‑aged adults (40–60 years). Both men and women are affected, with a slight male predominance (≈55 % of cases). Approximately 20–25 % of patients have an inherited form called Multiple Endocrine Neoplasia type 1 (MEN‑1); the remainder have sporadic gastrinomas.

Prevalence: The exact incidence is low—estimated at 0.5–2 cases per million people per year worldwide. In the United States, roughly 500–1,000 new diagnoses occur annually, making ZES one of the rarest causes of peptic ulcer disease <sup>[1]</sup>.

Symptoms

Because excess acid attacks the gastrointestinal (GI) tract, symptoms may be broad and sometimes mimic more common conditions. Below is a comprehensive list, grouped by system.

Gastro‑intestinal

• Refractory peptic ulcers: Ulcers that fail to heal despite standard therapy; often multiple and located beyond the duodenum (e.g., jejunum, ileum).
• Abdominal pain: Burning or cramping pain, usually post‑prandial, that may improve with antacids.
• Severe heartburn (pyrosis): Due to high gastric acid reflux.
• Diarrhea: Occurs in 50‑80 % of patients; can be watery, fatty (steatorrhea), or mixed because acid inactivates pancreatic enzymes.
• Nausea & vomiting: May result from ulcer complications or high gastric volume.
• Gastro‑intestinal bleeding: Hematemesis or melena from ulcer erosion.

Systemic

• Weight loss: From chronic diarrhea and malabsorption.
• Fatigue & anemia: Iron‑deficiency anemia secondary to chronic GI bleeding.
• Osteopenia/osteoporosis: Chronic acid load can impair calcium absorption.
• Kidney stones: Hypercalciuria may occur due to acid‑induced bone resorption.

MEN‑1 specific (if present)

• Parathyroid hyperplasia → hypercalcemia.
• Pituitary adenomas → headaches, visual changes, hormonal abnormalities.

Causes and Risk Factors

ZES results from gastrin‑secreting neuroendocrine tumors (NETs). Understanding the origin helps identify at‑risk individuals.

Primary causes

• Sporadic gastrinomas: Approximately 75 % of ZES cases. These tumors are usually solitary, <2 cm in size, and located in the “gastrinoma triangle” (pancreas, duodenum, and the junction of the common bile duct).
• MEN‑1 associated gastrinomas: Genetic mutation in the MEN1 tumor suppressor gene (chromosome 11q13). Tumors tend to be multiple, smaller, and more likely to recur after surgery.

Risk factors

• Family history of MEN‑1 or known MEN1 gene mutation.
• Previous diagnosis of other MEN‑1 tumors (parathyroid, pituitary).
• Chronic Helicobacter pylori infection does not cause ZES, but it can worsen ulcer disease and obscure diagnosis.

Diagnosis

Because ZES mimics common peptic ulcer disease, a high index of suspicion is required, especially when ulcers are refractory, multiple, or located distal to the duodenum.

Step‑wise diagnostic approach

1. Initial labs: Fasting serum gastrin level. A value > 1000 pg/mL (normal < 100 pg/mL) is strongly suggestive, especially when gastric pH is < 2.
2. Secretin stimulation test: Considered the gold standard. After intravenous secretin, gastrin levels paradoxically rise ≥ 120 pg/mL in ZES (normal response is a decrease).
3. Imaging for tumor localization:
   • Multiphasic contrast‑enhanced CT or MRI of the abdomen (sensitivity 60‑80 %).
   • Endoscopic ultrasound (EUS) – high resolution for small duodenal lesions.
   • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – detects lesions < 1 cm and assesses metastatic spread.
4. Endoscopy: Upper GI endoscopy identifies ulcer location, allows biopsies to rule out H. pylori or malignancy, and can sometimes visualize duodenal gastrinomas.
5. Biochemical assessment for MEN‑1: Serum calcium, parathyroid hormone, and prolactin levels; genetic testing for MEN1 mutation when clinical suspicion is high.

All diagnostic steps should be interpreted by a gastroenterologist or an endocrinologist experienced in neuroendocrine tumors.

Treatment Options

Management has two primary goals: control acid hypersecretion and eradicate or control the gastrinoma.

Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs): High‑dose omeprazole 40‑80 mg daily or equivalent (e.g., esomeprazole 40 mg BID). PPIs are the mainstay and often required for life.
• H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs are superior.

Surgical management

• Curative resection: Preferred for solitary, well‑localized tumors (< 2 cm) without metastasis. Options include pancreaticoduodenectomy, enucleation, or duodenotomy with tumor excision.
• Debulking surgery: For metastatic disease; aims to reduce tumor burden and improve symptom control.
• Minimally invasive techniques: Laparoscopic or robot‑assisted resections are increasingly used in experienced centers.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogs: Octreotide or lanreotide suppress gastrin secretion and may stabilize tumor growth.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) approved for advanced pancreatic NETs; may be considered in progressive ZES.
• Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor‑positive tumors; shows promising response rates.
• Chemotherapy: Reserved for high‑grade neuroendocrine carcinomas; not first line for typical gastrinomas.

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoidance of NSAIDs, aspirin, and smoking, which aggravate ulcer formation.
• Calcium and vitamin D supplementation to counteract bone loss.
• Regular monitoring of bone density (DEXA) and serum electrolytes.

Living with Zollinger‑Ellison Syndrome (Primary Hypergastrinemia)

Long‑term disease control requires a partnership between the patient, gastroenterologist, endocrinologist, and sometimes a surgeon. Below are practical tips for daily life.

• Medication adherence: Take PPIs exactly as prescribed, preferably 30 minutes before meals. Do not stop abruptly without medical guidance.
• Schedule regular follow‑ups: Every 6–12 months for serum gastrin, fasting gastric pH, and imaging to detect tumor recurrence or metastasis.
• Nutrition:
  • Consume a balanced diet rich in lean protein, whole grains, and low‑fat dairy.
  • Limit caffeine, alcohol, and very spicy foods, which can increase acid production.
  • Consider a dietitian referral for individualized meal planning.
• Bone health: Weight‑bearing exercise (e.g., walking, swimming) 3‑4 times per week; discuss bisphosphonate therapy if DEXA shows significant loss.
• Watch for warning signs: New or worsening abdominal pain, change in stool consistency, vomiting blood, or sudden weight loss should prompt immediate contact with your care team.
• MEN‑1 surveillance: If you carry a MEN1 mutation, annual screening for parathyroid, pituitary, and pancreatic lesions is essential.

Prevention

Because ZES is largely driven by genetic mutations or sporadic tumor development, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling for families with known MEN‑1 mutations; early testing can lead to vigilant surveillance.
• Avoid chronic use of ulcerogenic drugs (e.g., high‑dose NSAIDs) to reduce background mucosal injury.
• Prompt treatment of H. pylori infection to eliminate a separate ulcer risk factor that could mask ZES.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems.

• Peptic ulcer complications: Perforation, bleeding, or obstruction, each constituting a medical emergency.
• Malabsorption: Chronic diarrhea can cause electrolyte disturbances (hypokalemia, metabolic alkalosis) and nutrient deficiencies.
• Gastrointestinal strictures: Repeated ulcer healing may produce scar tissue leading to narrowing of the duodenum or jejunum.
• Metastatic disease: Approximately 30‑50 % of gastrinomas metastasize to the liver or lymph nodes, worsening prognosis.
• Bone disease: Osteomalacia, osteoporosis, and increased fracture risk due to chronic acid‑induced calcium loss.
• Renal complications: Nephrolithiasis and, rarely, renal insufficiency from chronic acid load.

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information provided is for educational purposes only and does not replace professional medical advice. Consult a qualified health‑care provider for personalized diagnosis and treatment.

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org.
2. National Institutes of Health – National Cancer Institute. Neuroendocrine Tumors Treatment (PDQ). https://www.cancer.gov.
3. Cleveland Clinic. Zollinger‑Ellison syndrome. https://my.clevelandclinic.org.
4. World Health Organization. Classification of Tumours of the Digestive System, 5th Edition. 2021.
5. U.S. National Library of Medicine. “Secretin stimulation test for diagnosing Zollinger‑Ellison syndrome.” PMID: 32256517.
6. European Neuroendocrine Tumor Society (ENETS) Guidelines for NETs – 2023 update.

```